Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) EBITDA (2025)

Drugs Made In America Acquisition filings provide 1 years of EBITDA readings, the most recent being -$2.1 million for Q4 2025.

  • Quarterly EBITDA changed N/A to -$2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$2.8 million for FY2025, 906.28% down from the prior year.
  • EBITDA hit -$2.1 million in Q4 2025 for Drugs Made In America Acquisition, down from -$263703.0 in the prior quarter.
  • Across five years, EBITDA topped out at -$131919.0 in Q2 2025 and bottomed at -$2.1 million in Q4 2025.